Skip to main content
NCBI home page
Cellular and Molecular Neurobiology logoLink to Cellular and Molecular Neurobiology
. 1992 Dec;12(6):581–587. doi: 10.1007/BF00711237

Monoamine neurotransmitters and their metabolites in brain regions in alzheimer's disease: A postmortem study

Adil J Nazarali 1,✉, Gavin P Reynolds 1
PMCID: PMC11567239  PMID: 1283363

Abstract

  1. Concentrations of the neurotransmitter amines noradrenaline (NA), dopamine (DA), and 5-hydroxytryptamine (5-HT) and the acid metabolites homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5-HIAA) were determined in four regions of postmortem brains of demented patients with or without Alzheimer's disease (AD).

  2. NA was deficient in the temporal cortex (BA 21) of AD, but not of non-AD, patients.

  3. Caudate, in particular, had an impaired dopaminergic system in AD patients, with low HVA levels.

  4. In all regions investigated [amygdala, caudate, putamen, temporal cortex (BA 21)] 5-HT was significantly depleted in AD patients, and 5-HIAA was also depleted in amygdala and caudate.

  5. These results indicate that neurotransmitter systems other than cholinergic systems are also widely affected in AD and suggest that these deficits may also play an important role in determining the symptomatology of AD.

Key words: Alzheimer's disease, postmortem brain, neurotransmitters, catecholamines, indoleamines, acid metabolites

References

  1. Adolfsson, R., Gottfries, C. G., Roos, B. E., and Winblad, B. (1979). Changes in the brain catecholamines in patients with dementia of Alzheimer type.Br. J. Psychiat.135216–223. [DOI] [PubMed] [Google Scholar]
  2. Arai, H., Kosaka, K., and Iizuka, R. (1984). Changes of biogenic amines and their metabolites in postmortem brains from patients with Alzheimer-type dementia.J. Neurochem.43388–393. [DOI] [PubMed] [Google Scholar]
  3. Baker, G. B., and Reynolds, G. P. (1989). Biogenic amines and their metabolites in Alzheimer's disease: Noradrenaline, 5-hydroxytryptamine and 5-hydroxyindole-3-acetic acid depleted in hippocampus but not in substantia innominata.Neurosci. Lett.100335–339. [DOI] [PubMed] [Google Scholar]
  4. Bondareff, W., Mountjoy, C. Q., and Roth, M. (1981). Selective loss of neurons of origin of adrenergic projection to cerebral cortex (nucleus locus coeruleus) in senile dementia.Lancet,1783–784. [DOI] [PubMed] [Google Scholar]
  5. Bowen, D. M., Allen, S. J., Benton, J. S., Goodhardt, M. J., Haan, E. A., Palmer, A. M., Sims, N. R., Smith, C. C. T., Spillane, J. A., Esiri, M. M., Neary, D., Snowdon, J. S., Wilcock, G. K., and Davison, A. N. (1983). Biochemical assessment of serotonergic and cholinergic dysfunction and cerebral atrophy in Alzheimer's disease.J. Neurochem.41266–272. [DOI] [PubMed] [Google Scholar]
  6. Cross, A. J., Crow, T. J., Perry, E. K., Perry, R. H., Blessed, G., and Tomlinson, B. E. (1981). Reduced dopamineβ-hydroxylase activity in Alzheimer's disease.Br. Med. J.28293–94. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Cross, A. J., Crow, T. J., Johnson, J. A., Joseph, M. H., Perry, E. K., Perry, R. H., Blessed, G., and Tomlinson, B. E. (1983). Monoamine metabolism in senile dementia of Alzheimer type.J. Neurol. Sci.60383–392. [DOI] [PubMed] [Google Scholar]
  8. Davies, P., and Maloney, A. J. F. (1976). Selective loss of central cholinergic neurons in Alzheimer's disease.Lancet21403. [DOI] [PubMed] [Google Scholar]
  9. Davies, P., Katzman, R., and Terry, R. D. (1980). Reduced somatostatin-like immunoreactivity in cerebral cortex from cases of Alzheimer disease and Alzheimer senile dementia.Nature288279–280. [DOI] [PubMed] [Google Scholar]
  10. DeJong, R. N., and Pope, A. (1975). Complex cerebral functions. InThe Nervous System, Clinical Neurosciences, Vol. 2 (D. B. Tower and T. N. Chase, Eds.), Raven Press, New York, pp. 449–456. [Google Scholar]
  11. Ferrier, I. N., Cross, A. J., Johnson, J. A., Roberts, G. W., Crow, T. J., Corsellis, J. A. N., Lee, Y. C., O'Shaughnessy, D., Adrian, T. E., McGregor, G. P., Baracese-Hamilton, A. J., and Bloom, S. R. (1983). Neuropeptides in Alzheimer type dementia.J. Neurol. Sci.62159–170. [DOI] [PubMed] [Google Scholar]
  12. Gottfries, C. G. (1979). Amine metabolism in normal ageing and in dementia disorders. InBiochemistry of Dementia (P. J. Roberts, Ed.), John Wiley and Sons, Chichester, pp. 213–234. [Google Scholar]
  13. Gottfries, C. G. (1981). Levels of monoamines, monoamine metabolites and activity in related enzyme systems correlated to normal ageing and in patients with dementia of Alzheimer type. InApomorphine and Other Dopaminomimetics, Clinical Pharmacology, Vol. 2 (G. U. Corsini and G. L. Gessa, Eds.), Raven Press, New York, pp. 243–249. [Google Scholar]
  14. Gottfries, C. G. (1990). Neurochemical aspects of dementia disorders.Dementia156–64. [Google Scholar]
  15. Gottfries, C. G., Adolfsson, R., Aquilonius, S. M., Carlsson, A., Oreland, L., Svennerholm, L., and Winblad, B., (1980). Parkinsonism and dementia disorders of the Alzheimer type: Similarities and differences. InParkinson's Disease—Current Progress, Problems and Management (U. K. Rhinne, M. Klingler, and G. Stamm, Eds.), Elsevier/North-Holland Biomedical Press, Amsterdam, pp. 197–208. [Google Scholar]
  16. Gottfries, C. G., Adolfsson, R., Aquilonius, S. M., Carlsson, A., Eckernas, S. A., Nordberg, A., Oreland, L., Svennerholm, L., Wiberg, A., and Winblad, B., (1983). Biochemical changes in dementia disorders of Alzheimer type (AD/SDAT).Neurobiol. Aging4 261–271. [DOI] [PubMed] [Google Scholar]
  17. Hardy, J., Adolfsson, R., Alafuzoff, I., Bucht, G., Marcusson, J., Nyberg, P., Perdahl, E., Wester, P., and Winblad, B. (1985). Transmitter deficits in Alzheimer's disease.Neurochem. Int.7545–563. [DOI] [PubMed] [Google Scholar]
  18. Ishii, T. (1966). Distribution of Alzheimer's neurofibrillary changes in the brain stem and hypothalamus of senile dementia.Acta Neuropathol. (Berl.)6181–187. [DOI] [PubMed] [Google Scholar]
  19. Iversen, L. L., Rossor, M. N., Reynolds, G. P., Hills, R., Roth, M., Mountjoy, C. Q., Foote, S. L., Morrison, J. H., and Bloom, F. E. (1983). Loss of pigmented dopamine-β-hydroxylase positive cells from locus coeruleus in senile dementia of Alzheimer's type.Neurosci. Lett.3995–100. [DOI] [PubMed] [Google Scholar]
  20. Mann, D. M. A., Lincoln, J., Yates, P. O., Stamp, J. E., and Toper, S. (1980). Changes in the monoamine containing neurones of the human CNS in senile dementia.Br. J. Psychiat.136533–541. [DOI] [PubMed] [Google Scholar]
  21. Mann, D. M. A., Yates, P. O., and Hawkes, J. (1982). The noradrenergic system in Alzheimer and multi-infarct dementias.J. Neurol. Neurosurg. Psychiat.45113–119. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Pearce, J. (1974). Mental changes in Parkinsonism.Br. Med. J.2445. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Perry, E. K. (1987). Cortical neurotransmitter chemistry in Alzheimer's disease. InPsychopharmacology: The Third Generation of Progress, (H. Y. Meltzer, Ed.), Raven Press, New York, pp. 887–895. [Google Scholar]
  24. Perry, E. K., Perry, R. H., Blessed, G., and Tomlinson, B. E. (1977). Necropsy evidence of central cholinergic deficits in senile dementia.Lancet1189. [DOI] [PubMed] [Google Scholar]
  25. Quirion, R., Martel, J. C., Robitaille, Y., Etienne, P., Wood, P., Nair, N. P. V., and Gautheir, S. (1986). Neurotransmitter and receptor deficits in senile dementia of the Alzheimer type.Can. J. Neurol. Sci.13503–510. [DOI] [PubMed] [Google Scholar]
  26. Reynolds, G. P. (1983). Increased concentrations and lateral asymmetry of amygdala dopamine in schizophrenia.Nature305527–529. [DOI] [PubMed] [Google Scholar]
  27. Reynolds, G. P., Arnold, L., Rossor, M. N., Iversen, L. L., Mountjoy, C. Q., and Roth, M. (1984). Reduced binding of [3H]-ketanserin to cortical 5-HT2 receptors in senile dementia of the Alzheimer type.Neurosci. Lett.4447–51. [DOI] [PubMed] [Google Scholar]
  28. Rossor, M. N. (1982). Dementia.Lancet21200–1204.6128503 [Google Scholar]
  29. Rossor, M., and Iversen, L. L. (1986). Non-cholinergic neurotransmitter abnormalities in Alzheimer's disease.Br. Med. Bull.4270–74. [DOI] [PubMed] [Google Scholar]
  30. Rossor, M. N., Emson, P. C., Mountjoy, C. Q., Roth, M., and Iversen, L. L. (1980). Reduced amounts of immunoreactive somatostatin in the temporal cortex in senile dementia of Alzheimer type.Neurosci. Lett.20373–377. [DOI] [PubMed] [Google Scholar]
  31. Selkoe, D. J. (1991). The molecular pathology of Alzheimer's disease.Neuron6487–498. [DOI] [PubMed] [Google Scholar]
  32. Spillane, J. A., White, P., Goodhardt, M. J., Flack, R. H. A., Bowen, D. M., and Davison, A. N. (1977). Selective vulnerability of neurons in organic dementia.Nature266558–559. [DOI] [PubMed] [Google Scholar]
  33. Spokes, E. G. S. (1979). An analysis of factors influencing measurements of dopamine, noradrenaline, glutamate decarboxylase and choline acetylase in human postmortem brain tissue.Brain102333–346. [DOI] [PubMed] [Google Scholar]
  34. Tomlinson, B. E., and Corsellis, J. A. N. (1984). Ageing and the dementias. InGreenfield's Neuropathology 4th ed. (J. H. Adams, J. A. N. Corsellis, and L. W. Duchen, Eds.), J. Wiley, New York, pp. 951–1025. [Google Scholar]
  35. Tomlinson, B. E., Irving, D., and Blessed, G. (1981). Cell loss in the locus coeruleus in senile dementia of Alzheimer type.J. Neurol. Sci.49419–428. [DOI] [PubMed] [Google Scholar]
  36. Whitehouse, P. J., Price, D. L., Clark, A. W., Coyle, J. T., and Delong, M. R. (1981). Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis.Ann. Neurol.10122–126. [DOI] [PubMed] [Google Scholar]
  37. Winblad, B., Adolfsson, R., Carlsson, A., and Gottfries, C. G. (1982). Biogenic amines in brains of patients with Alzheimer's disease. InAlzheimer's Disease: A Report of Progress in Research, Vol. 19 (S. Corkin, K. L. Davis, J. H. Growdon, E. Usdin, and R. J. Wurtman, Eds.), Raven Press, New York, pp. 25–33. [Google Scholar]

Articles from Cellular and Molecular Neurobiology are provided here courtesy of Springer

RESOURCES